header logo image


Page 443«..1020..442443444445..450460..»

These were the best performing ASX 200 shares last week – Motley Fool Australia

July 10th, 2020 9:45 pm

TheS&P/ASX 200 Index(ASX: XJO) was out of form last week and dropped notably lower. The benchmark index fell a disappointing 2.3% to 5,919.2 points.

Not all shares dropped lower with the market last week. Heres why these ASX 200 shares were flying high:

The Netwealth Group Ltd (ASX: NWL) share price was the best performer on the ASX with a 18.4% gain. Investors were buying the investment platform providers shares last week following the release of its fourth quarter update. At the end of the quarter, Netwealths funds under administration (FUA) had climbed to a sizeable $31.5 billion. This means the company grew its FUA by $8.2 billion or 35% during FY 2020. This includes a negative market movement of $0.9 billion for the 12 months.

The Perseus Mining Limited (ASX: PRU) share price was an impressive performer last week with a 12.3% gain. The catalyst for this strong gain was another rise in the gold price. Traders were fighting to get hold of the precious metal after coronavirus cases spiked globally. Demand was so strong the gold price broke through the US$1,800 an ounce mark and hit a nine-year high. For the same reason, St Barbara Ltd (ASX: SBM) and Gold Road Resources Ltd (ASX: GOR) shares stormed 10.3% and 9.3% higher, respectively.

The Mesoblast limited (ASX: MSB) share price was on form and jumped 8.9% last week. Investors were buying the allogeneic cellular medicines developers shares after it provided an update on its allogeneic mesenchymal stem cell (MSC) product candidate, remestemcel-L. That update revealed that the product has been given an expanded access protocol for compassionate use in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome.

The Megaport Ltd (ASX: MP1) share price wasnt far behind with a gain of 8.4%. This was despite there being no news out of the global leading provider of elastic interconnection services. However, with the pandemic accelerating the shift to the cloud, investors appear confident that Megaport will be experiencing very strong demand for its services.

We hear it over and over from investors, "I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I'd be sitting on a gold mine!" And it's true.

And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

See the 5 stocks

*Extreme Opportunities returns as of June 5th 2020

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of MEGAPORT FPO. The Motley Fool Australia owns shares of Netwealth. The Motley Fool Australia has recommended MEGAPORT FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

See the article here:
These were the best performing ASX 200 shares last week - Motley Fool Australia

Read More...

A Longer Life May Not Be in Your Genes | Live Science

July 10th, 2020 8:50 pm

Long life spans tend to run in families, a phenomenon that's often attributed to people's genes. But now, a large new study of data from the genealogy website Ancestry reveals that genetics may play less of a role in life span than previously thought.

The reason? Previous studies failed to take into account a quirk of human relationships: that people tend select romantic partners with similar traits to their own. The findings mean that previous studies may have substantially overestimated the heritability of life span, the researchers said.

The study was published in today (Nov. 6) in the journal Genetics. It was funded by Calico Life Sciences, a research and development company owned by Alphabet Inc. (Google's parent company) whose mission is to understand the biology of aging. [7 Ways the Mind and Body Change With Age]

In a given population, people will vary in a number of ways; they'll have different heights, eye colors and, yes, life spans.

Heritability is a measure of how much of the variability in a given trait, such as life span, is explained by variability in people's genes, in contrast to environmental factors such as healthy eating or exercise. Previous studies have estimated that the heritability of life span is as high as 30 percent.

In the new study, the researchers analyzed information from more than 400 million people using publicly available family trees from Ancestry. Because the researchers needed to know the life span of these individuals, the study looked at only those who were born in the 1800s or early 1900s and were deceased. (Before sharing this data, Ancestry removed all identifiable information from the family trees.)

An initial analysis revealed that, when comparing the life spans of siblings and first cousins, the heritability of life span appears to be around 20 to 30 percent similar to what's been found previous studies.

But the life spans of spouses also tended to be similar. This could be due to spouses sharing a similar environment, the study said. Because they live in the same household, they may share many nongenetic factors, from diet to sleep habits, that could influence life span.

But then the researchers noted something curious: They found that even siblings-in-law and first-cousins-in-law had correlated lifespans, despite not generally living in the same household or being blood relatives.

But if they didn't share a close family history or a similar environment, why did remote and non-blood relatives also have linked life spans? The large data set allowed researchers to examine the effect of what's called assortative mating, the phenomenon in which people tend to select spouses who are similar to themselves. If assortative mating was at play, it would mean that factors that are important for life span tend to be similar among spouses, Graham Ruby, lead author of the study and a principal investigator at Calico Life Sciences, said in a statement.

Indeed, the researchers found that this was the case, and when they accounted for assortative mating, the heritability of life span dropped to 7 percent.

However, the study is not saying that people select a mate based on their life span, as that would be impossible, Ruby said. "Generally, people get married before either one of them has died," Ruby said jokingly.

But other factors could be at play, including both genetic and nongenetic variables. For example, if wealth is tied to life span and wealthy people tend to marry other wealthy people, this could make life span appear to be more heritable than it really is, the researchers said. Or if height a trait that is partly influenced by genetics is linked to life span and tall people tend to marry other tall people, then this would also muddle the analysis of the heritability of life span.

However, the findings don't mean that there aren't genes for longevity. The study focused on the heritability of life span on a population level and did not look specifically at people's genomes. Previous studies have found a link between certain genes and a long life.

Originally published on Live Science.

Read more:
A Longer Life May Not Be in Your Genes | Live Science

Read More...

Dr. Ryan Valencic was selected as Top Executive Coach of the Year by the International Association of Top Professionals (IAOTP) – Life Pulse Health

July 10th, 2020 8:49 pm

UNITED STATES, 07-10-2020 (PRDistribution.com) Dr. Ryan Valencic, CEO of Novis Health, was recently selected as Top Executive Coach of the Year by the International Association of Top Professionals (IAOTP) for his outstanding work in developing and franchising the first functional medicine company in the U.S.

Inclusion with the International Association of Top Professionals is an honor, only a few members in each discipline are chosen for this distinction. These special honorees are distinguished based on their professional accomplishments, academic achievements, leadership abilities, longevity in the field, other affiliations, and contributions to their communities. All honorees are invited to attend IAOTPs annual award gala at the end of this year for a night to honor their achievements. http://www.iaotp.com/award galaWith over a decade of professional experience, Dr. Valencic has proven himself an extraordinary professional and expert in the healthcare field. As a dynamic results-driven leader, he has demonstrated success and excelled in every position he has ever served. His impressive repertoire of prior roles include the CEO of Carolina Integrative Health Care, Founder of Sybra Media, and serving as Sybras Business Development Executive, Chair of the Board of Directors for Apollo Physical Medicine and a Private Consultant and Trainer in the Healthcare Industry.Dr. Valencics key areas of expertise include, but are not limited to, healthcare management and consulting, business development, entrepreneurship, marketing and marketing strategy, and corporate relationship management. Currently, Dr. Valencic holds the position of CEO for Novis Health, the first functional medicine franchise in the U.S. Dr. Valencic, along with his co-founder and CCO, Dr. Ruben Valdes, recently launched Novis Health nationwide with international expansion plans in early 2022.Before embarking on his professional career path, Dr. Valencic received his Bachelors Degree from Gannon University for Pre- Medicine and Pre-Medical Studies. He continued his education and earned his Doctorate of Chiropractic from Palmer College of Chiropractic. In addition to his Doctorate, he began working on his Diplomate of Clinical Nutrition.The President of IAOTP, Stephanie Cirami, stated, Choosing Dr. Valencic for this award was an easy decision for our panel to make. He is goal-oriented, has tremendous foresight, and is a strategic thinker. With these traits, we know he will add talent to our network of professionals.We are looking forward to meeting him at the Annual Awards Gala.Throughout his remarkable career, Dr. Valencic has received awards, accolades and has been recognized worldwide for his knowledge of the healthcare industry. This year he is being considered for a feature in TIP (Top Industry Professionals) Magazine and the Business Innovator of the Year Award by the International Association of Top Professionals (IAOTP). He will be honored at their Annual Awards Gala being held at the Plaza Hotel in New York City in December.Looking back, Dr. Valencic attributes his success to his perseverance, the mentors he has had the honor of working alongside and remaining passionate in all of his endeavors. When not working, he enjoys spending time with his wife, Ashley, and their four children, Addison, Mason, Reagan, and Sloan. Now that Novis Health has launched, Dr. Valencic dedicates his professional time to its expansion and enhancement.For more information on Dr. Ryan Valencic please visit: https://www.linkedin.com/in/dr-ryan-valencic-dc-3444b9144/About IAOTPThe International Association of Top Professionals (IAOTP) is an international boutique networking organization that handpicks the worlds finest, most prestigious top professionals from different industries. These top professionals are given an opportunity to collaborate, share their ideas, be keynote speakers, and influence others in their fields. This organization is not a membership that anyone can join. You have to be asked by the President or be nominated by a distinguished honorary member after a brief interview.IAOTPs experts have given thousands of top prestigious professionals worldwide, the recognition and credibility that they deserve, and have helped build their branding empires. IAOTP prides itself to be a one of a kind boutique networking organization that hand picks only the best of the best and creates a networking platform that connects and brings these top professionals together.For More Information on IAOTP please visit: http://www.iaotp.com.

Media Contacts:

Company Name: IaotpFull Name: Stephanie CiramiPhone: 212 634 4427Email Address: Send EmailWebsite: http://www.iaotp.com

For the original news story, please visit https://prdistribution.com/news/dr-ryan-valencic-was-selected-as-top-executive-coach-of-the-year-by-the-international-association-of-top-professionals-iaotp.html.

Powered by WPeMatico

Read more:
Dr. Ryan Valencic was selected as Top Executive Coach of the Year by the International Association of Top Professionals (IAOTP) - Life Pulse Health

Read More...

CS02 Changes the Landscape of Diabetes Treatment: CenterLab Announces Positive Topline Results of Phase 2 Trial – Yahoo Finance

July 10th, 2020 8:47 pm

TAIPEI, July 10, 2020 /PRNewswire/ -- Center Laboratories Inc. (CenterLab: 4123.TWO), a pharmaceutical company dedicated in specialty drug product development, announced today that the anti-diabetic drug CS02 meets its primary endpoint. The topline results of a phase 2 clinical trial of CS02 showed significantly decreases of glycated hemoglobin (HbA1c) in treated patients as compared to placebo group by 0.45% (p value = 0.0098).

Center Laboratories Inc. Logo

CS02 is an orally administered small molecule drug under development following the abbreviated 505(b)(2) regulatory pathway for new drug approval. This phase 2 trial is a proof of concept (PoC) study according to the US FDA's guidance to explore its glycemic controlling effect primarily. Furthermore, CenterLab included Homeostasis model2 assessment -cell (HOMA2-) as a secondary endpoint demonstrating its capability in beta cell preservation. The results from the Phase 2 trial showed that CS02 significantly decreased HbA1c and had stellar performance on preserving pancreatic beta cell function with HOMA2- increased by 13.45%.

According to American Diabetes Association (ADA), cardiovascular disease (CVD) is the major cause of morbidity and mortality for diabetic patients and results in $37.3 billion in related expenditure per year. As CS02 was designed to be submitted through 505(b)(2) pathway to treat diabetes with new mechanism, not only could CS02 reduce blood glucose level, but it could also reduce the risk of cardiovascular complications by reducing blood pressure as its inherent feature. Through 505(b)(2) pathway, the safety, tolerability and pharmacokinetic profiles from previously approved drug and published references can be leveraged to support the safety and/or effectiveness of CS02, by that, redundant investigation processes could be waived and significantly shorten the drug product development time to market.

"CenterLab is highly committed to patients' unmet needs, thus, CenterLab aims to bring on better treatments which is more cost-effective and safer compared to other treatments. We believe CS02, as a potential blockbuster for diabetes treatment, has a role in improving patients' life quality," said Robert Hsu, the GM of CenterLab.

For further development of CS02, CenterLab is actively seeking global partners for co-development or licensing opportunities.

About CenterLab

Center Laboratories Inc. is a professional oral liquid pharmaceutical company and experts in worldwide specialty drug development. Also, we bring together resources and experiences to help potential biotechnology and healthcare companies tap into the global market.

Logo - https://photos.prnasia.com/prnh/20200710/2854796-1LOGO

SOURCE Center Laboratories Inc.

Read the original here:
CS02 Changes the Landscape of Diabetes Treatment: CenterLab Announces Positive Topline Results of Phase 2 Trial - Yahoo Finance

Read More...

Type 2 diabetes medication recalled over carcinogen concerns – 1010WINS

July 10th, 2020 8:47 pm

NEW YORK (1010 WINS) -- Two more drug manufacturers have recalled the widely-used Type 2 diabetes medication metformin, over concerns that it contains too much of the human carcinogen NDMA, a "probable" cancer-causing substance, the FDA announced this week.

The two new recalls followsimilar recalls in May fromTeva Pharmaceuticals, Marksans Pharma Limited, Apotox Corp. and Amneal Pharmaceuticals.

This week, Lupin Pharmaceuticals Inc.issued the recall for all of its batches of Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 1000 mg. According to the FDA, "additional analysis revealed that certain tested batches were above the Acceptable Daily Intake Limit for the impurity N-Nitrosodimethylamine (NDMA)."

Another drug maker, Granules Pharmaceuticals, Inc., has recalled 12 lots of its Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, 100 and 500 count.

Metformin is a prescription medication that is used to improve blood glucose control in adults with Type 2 diabetes mellitus, the FDA said.Patients who are currently taking the medication should contact their medical providers before they stop, as stopping suddenly could be dangerous to those with serious conditions, the FDA noted.

RECALLED

LUPIN PHARMACEUTICALS Metformin Hydrochloride Extended-Release Tablets USP

500 mg, NDC No. 68180-338-01, distributed between Nov. 21, 2018, and May 27, 2020.

1000 mg, NDC No. 68180-339-09, distributed between Nov. 21, 2018, and May 27, 2020.

500 mg, NDC No. 68180-336-07, distributed between Nov. 5, 2018, and May 22, 2020.

1000 mg, NDC No. 68180-337-07, distributed between Nov. 5, 2018, and May 22, 2020.

The medication was distributed in bottles of 60, 90 and 100 tablets and was distributed nationwide in the United States to wholesalers, distributors, drug chain, mail order pharmacies and supermarkets.

For more information, call Inmar Rx Solutions, Inc. at855-532-1856, between 9 a.m. and 5 p.m. EST, weekdays.

GRANUELS PHARMACEUTICALS

Metformin Hydrochloride Extended-Release Tablets USP, 750 mg

100 count bottles, NDC No. 70010-492-01, Lot numbers and expiration dates - 4920003A/May 2021, 4920004A/June 2021, 4920005A/June 2021, 4920009A/November 2021, 4920010A/May 2022, 4920011A/June 2022, 4920012A/June 2022, 4920013A/July 2022, 4920014A/July 2022, 4920015A/August 2022 and 4920016A/January 2023.

500 count bottles, NDC No. 70010-492-05, lot No. 4920005B, expires June 2021.

See the original post here:
Type 2 diabetes medication recalled over carcinogen concerns - 1010WINS

Read More...

Ex-Drug Addict Loses 200lb And Reverses T2 Diabetes On Plant-Based Diet – Plant Based News

July 10th, 2020 8:47 pm

Adam's plant-based diet allows him to be his most authentic self (Photo: Adam/Million Dollar Vegan)

A former drug addict who battled a 'lifelong struggle with self-hatred' has revealed how he transformed his life on a plant-based diet.

Adam, from Austin TX, shared his story in a video shared by advocacy organization Million Dollar Vegan (MDV), which encourages and supports people to sign its 31-day pledge and give a plant-based diet a go. Participants are offered a free Vegan Starter Kit featuring meal plans, tips on where to eat out, and answers to tricky questions.

In the video, Adam describes how changing his diet helped him overcome a slew of diseases, as well as helped him become 'the most authentic version of [himself he's] ever been.

"I was battling the end of a 10-year struggle with substance abuse, a lifelong struggle with self-hatred, and a disbelief that I would ever wake up and experience being alive again," Adam says. "I had avoided any opportunity to let myself know the state of disconnection that I was living in.

"At the time of my diagnosis, my A1C was at 12. That's a biomarker for diabetes, and anything above 6.4 is type 2 diabetic. My blood pressure was 210 over a hundred and something. My cholesterol was through the roof. Which is, if you think about it, completely reasonable given the way that I was living my life.

"I found myself alone, in the dark, on the floor, in a puddle of vomit with no one around me, not because they didn't wanna be there for me, but because I had pushed everything that meant anything out of my life."

Adam ended up in addiction recovery treatment where he was diagnosed with type 2 diabetes, high blood pressure, high cholesterol, erectile dysfunction, bipolar disorder, suicidal depression, anxiety disorder, sleep disorder, and attention deficit disorder.

"The last thing that had to break before I changed my diet, was literally me. And my motivation had nothing to do with my diabetes, or my heart disease, or my obesity, or my substance abuse," he says. "Those things were real, and they are motivation, but the motivation for me was, all right, I was obese, and I didn't wanna be. I had heart disease and diabetes, and I didn't want those things.

"And I nearly died from substance abuse, and to be honest, I didn't wanna live, but I surely discovered after attempting suicide that I didn't wanna die. Within three months of adopting a plant-based diet, of adopting a mindfulness meditation practice and moving my body with purpose, reconnecting with nature on a regular basis."

Within a year of changing his diet, Adam was off every medicine he'd been prescribed while in rehab including antidepressants, mood stabilizers, sleeping medications, anxiety medications, and ADHD medications. He lost 100lb (which totals 200lb as of today) and completely reversed his diabetes.

He says: "We underestimate the power of the most simple choices that we have in our lives, and those simple choices are the ones that we have control over, most of the time: what we put on our plate, how we talk to ourselves, how we live with other people.

Change doesn't happen five minutes from now. It certainly doesn't happen five minutes before. It doesn't happen five weeks or five years from now, and it doesn't happen five weeks or five years before. It's right here right now, because now is when I have a choice, and I know the choice that brings positive change for me is the diet that creates the greatest health I've ever experienced in my life."

He adds that his diet also allows him to 'feel good about the impact he has on the world around him', and 'allows him to get up and be the person that he wants to be for his family'

"It allows me to be the most authentic version of myself I've ever been," he concludes. "And you know what? It's the person that I've always been. I didn't become somebody new. I became the person I've always been, just the most authentic version of it that I've ever experienced in my life."

Link:
Ex-Drug Addict Loses 200lb And Reverses T2 Diabetes On Plant-Based Diet - Plant Based News

Read More...

Diabetic Foot Ulcer Treatment Market to reach USD 11.05 billion by 2027; Rising Adoption of Novel Wound Care Devices to Propel Growth: Fortune…

July 10th, 2020 8:47 pm

Pune, July 10, 2020 (GLOBE NEWSWIRE) -- The global diabetic foot ulcer treatment market size is projected to showcase remarkable growth on account of the increasing prevalence of diabetes followed by a foot ulcer. A diabetic foot ulcer is an open wound occurring in the sole of the feet of a diabetic person and requires immediate pressure, off-loading, infection control, and vasculature to heal.

As per a recent report by Fortune Business Insights, titled, Diabetic Foot Ulcer (DFU) Treatment Market Size, Share & Covid-19 Impact Analysis, By Ulcer Type (Neuropathic Ulcer, Ischemic Ulcer, Neuro-ischemic Ulcer), By Product (Wound-care Dressings, Wound-care Devices, Active Therapies, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Homecare Settings), and Regional Forecast, 2020-2027, the value of the market was USD 7.03 billion in 2019 and is anticipated to reach USD 11.05 billion by the end of 2027. The market is presumed to rise at a CAGR of 5.9% during the forecast period, 2020 to 2027.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetic-foot-ulcer-dfu-treatment-market-101948

The Report Answers the Following Questions:

COVID-19 Impact on Market:

On account of the current COVID-19 pandemic, most of the non-emergency procedures in the healthcare sector have been put on the delay. A report by the general surgeons at the American College of Surgeons and the U.S. Centers for Medicare and Medicaid Services (CMS) states that all non-essential surgical and medical services will be cancelled as a necessary precaution against the spread of the virus. Most of the healthcare resources in the other nations are following similar procedures. This is likely to pose a significant threat to this market in the coming years.

To control the spread of the novel coronavirus worldwide, most nations have acquired social distancing and quarantine policies to attenuate the impact of this pandemic. Several businesses are adopting machine learning tools for analyzing the effects of these measures.

We, at Fortune Business Insights, are offering insightful data in the form of special reports on the market affected by the COVID-19 pandemic. These reports will come in handy when taking strategic decisions on investment and return revenue in the coming years.

Click here to get the short-term and long-term impacts of COVID-19 on this Market.Please visit: https://www.fortunebusinessinsights.com/industry-reports/diabetic-foot-ulcer-dfu-treatment-market-101948

Drivers & Restraints-Increasing Adoption of Extracellular Matrix Proteins to Propel Growth

A rise in the geriatric population and their vulnerability to various chronic diseases stand as the key drivers for promoting the diabetic foot ulcer treatment market growth. This, coupled with the increasing adoption of novel wound care devices, is aiding in the expansion of the market. Additionally, a rise in the availability of treatment option for diabetic foot ulcer is likely to augment the market growth in the coming years.

On the contrary, factors such as high cost of the advanced wound care therapies and devices and the lack of reimbursement policies may cause hindrance to the market growth in the coming years. Despite this, the advent and the increasing popularity of extracellular matrix proteins, bioengineered skin substitutes, and others are likely to create lucrative growth opportunities for the market for DFU treatment in the coming years.

Segment:

Wound Care Dressings Segment Bagged Major Share Owing to Cost-efficiency

Based on segmentation by product, the wound care dressings segment earned 42.7% diabetic foot ulcer treatment market share in 2019 and emerged dominant. This is owing to the cost-efficiency of these treatment procedures, less time taken to heal the wounds, and the overall exudate management.

Major Share Held by North America Owing to Increasing Prevalence of Diabetic Foot ulcer

Geographically, North America emerged dominant in the market for diabetic foot ulcer treatment, with a revenue of USD 2.79 billion generated in 2019. This is accountable to the presence of a well-established healthcare sector, increasing prevalence of the disease, and the growing launch of advanced solutions for wound care in the region.

Asia Pacific is expected to rise at a rapid pace in the forecast duration owing to the improving medical infrastructure and development, a rise in the diabetic population, and the increasing cases of foot ulcer among them.

Quick Buy - Diabetic Foot Ulcer Treatment Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101948

Competitive Landscape-

Coloplast Corp., ConvaTec Group Plc., and Smith & Nephew Earned Major Share Owing to Robust Research Activities

This global market earns major share from companies such as Mlnlycke Health Care AB, Smith & Nephew, Coloplast Corp, and ConvaTec Group Plc. Factors responsible for their dominance are the availability of a wide range of products and the significant investments in research and development activities in innovative product development. Furthermore, the strategic partnerships such as contracts and agreements, joint ventures, and others would help the companies in gaining traction in the global market.

Major Industry Developments of this Market Include:

July 2018 SastoMed GmbH was acquired by Mlnlycke for expanding the product offerings of the company by helping the medical professionals to accelerate the process of wound healing.

January 2019 A new advanced wound care product called FibDex was launched in the European market and it is the first of its kind to receive the CE mark and FDA approval.

List of the Leading Companies Operating in the DFU Treatment Market Include:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/diabetic-foot-ulcer-dfu-treatment-market-101948

Detailed Table of Content:

TOC Continued.!!!

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/diabetic-foot-ulcer-dfu-treatment-market-101948

Have a Look at Related Reports:

Advanced Wound Care Market Size, Share and Global Trend By Product (Advanced Wound Dressings, Wound Care Devices & Active Wound Care), Indication (Diabetic Foot Ulcers, Pressure Ulcers, Surgical Wounds, Others), End User and Geography Forecast till 2025

Active Wound Care Market Size, Share and Global Trend by Product Type (Biological Skin Equivalents, Growth Factors, Biological Dressings), Indication (Diabetic Foot Ulcers, Pressure Ulcers, Lower Limb Ulcers), End User (Hospitals, Clinics, Home Care Settings) and Geography Forecast till 2025

Wound Care Devices Market Size, Share and Global Trend By Product Type (Negative Pressure Wound Therapy (NPWT), Hyperbaric Oxygen Therapy (HBOT), Extracorporeal Shock Wave Therapy (ESWT)), Indication (Diabetic Foot Ulcers, Pressure Ulcers, Surgical Wounds), End Users (Hospitals, Clinics, Home Care Settings) and Geography Forecast till 2025

Chronic Wound Care Market Size, Share and Global Trend By Type of Chronic Wound (Venous Ulcer, Arterial Ulcer, Diabetic Ulcer, Pressure Sore), By Product (Wound Dressings, Wound Treatment Devices, Cleansing Agents, Antibiotics), By End User (Hospitals and Wound Care Centres, Ambulatory Surgery Centres, Homecare Settings), Geography Forecast till 2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/diabetic-foot-ulcer-dfu-treatment-market-9508

Continued here:
Diabetic Foot Ulcer Treatment Market to reach USD 11.05 billion by 2027; Rising Adoption of Novel Wound Care Devices to Propel Growth: Fortune...

Read More...

How to Practice Paddleboarding Safely When You Have Diabetes – Supconnect.com

July 10th, 2020 8:47 pm

After becoming the Association of Paddle Professional's Overall World Champion of 2017, Fiona Wylde has proven that even people with diabetes can overcome challenges posed by the disease and reach the pinnacle of the fast-growing sport of stand up paddleboarding (SUP). If you have diabetes, SUP is emerging as a great sport that you can enjoy without fear and even excel at it if you have what it takes. However, just like any other physical activity that involves aerobic, sprint, or resistance training, SUP can be risky to your health as a result of varying blood glucose responses, and it is up to you to manage those risks so that you can keep having fun and maintain your performance at the highest levels possible.

Foot problems are common in diabetes patients, and since you need healthy feet for SUP, you must take excellent care of them. Over time, diabetes can cause nerve damage in your feet resulting in tingling, pain, and loss of feeling in some cases. Diabetes may also reduce blood flow to your feet, making it hard for cuts, sores, and infections to heal. In some cases, the infection may lead to gangrene forcing you to have a toe, foot, or part of your leg amputated. Thankfully, there are many measures you can take to avoid these problems, starting with checking your feet regularly for cuts, scratches, blisters, and calluses, especially after a day of SUP. This will help you spot problems early when they're still easy to treat. Keep your feet clean at all times and wear shoes that are comfortable and perfectly fitting. A foot massage from your significant other after a day of SUP can also reduce inflammation and promote circulation.

Photo: Shutterstock

You can prevent both hyperglycemia and hypoglycemia during and after SUP through strategic carbohydrate intake and adjusting your dosage and timing of insulin. If your pumped or injected insulin levels are low when you begin SUP, you may need only 10 to 15 grams of carbs to prevent hypoglycemia. If you're getting on your board within two or three hours of bolus insulin, you may need around 50 grams of carbs per hour of SUP. Consult your doctor to ensure that you're taking the correct amount of carbs based on your unique needs. After a few hours of SUP, the carbohydrate levels in your muscles build back up slowly which makes you more sensitive to insulin, contributing to hypoglycemia up to two days later. To avoid this, make sure you're eating adequate amounts of carbs along with insulin before, during, and after SUP.

In addition to eating carbs to maintain blood sugar levels during exercise, you may need to also lower your basal and bolus insulin doses to decrease your hypoglycemia risk. Consult your doctor about your individual needs before you make such adjustments. In some cases, you may need up to a 20 percent reduction both before and after SUP. If you use an insulin pump, you may need to suspend or reduce basal insulin infusion 60 minutes before SUP to prevent hypoglycemia. Regardless of your regimen changes, be sure to track your blood sugar frequently and make necessary adjustments to stay in your target range.

Fiona Wylde racing in Japan. | Photo courtesy: Kure134 / Starboard

Diabetes may be challenging to live with at times, but it shouldn't prevent you from experiencing the joy and sense of freedom that SUP provides. By being prepared and working with your care team to create an effective diabetes management plan, you can engage in SUP without risking your well-being, whether you're doing it for fun or competitively.

See the original post:
How to Practice Paddleboarding Safely When You Have Diabetes - Supconnect.com

Read More...

2020 Insights into the Global Diabetic Neuropathy Industry – Market and Competitive Landscape – ResearchAndMarkets.com – Business Wire

July 10th, 2020 8:46 pm

DUBLIN--(BUSINESS WIRE)--haThe "Global Diabetic Neuropathy Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights into the Diabetic Neuropathy pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares. This research analyzes and forecasts the Diabetic Neuropathy market size and drug sales. It also provides insights into Diabetic Neuropathy epidemiology and late stage pipeline.

This research covers the following: Diabetic Neuropathy treatment options, Diabetic Neuropathy late stage clinical trials pipeline, Diabetic Neuropathy prevalence by countries, Diabetic Neuropathy market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries. The research scope includes the countries US, Germany, France, Italy, Spain, UK, Japan, Europe, Global (G7 Countries).

Research Scope:

Benefits of this Research:

Key Topics Covered:

1. Diabetic Neuropathy Treatment Options

2. Diabetic Neuropathy Pipeline Insights

2.1. Diabetic Neuropathy Phase 3 Clinical Trials

2.2. Diabetic Neuropathy Phase 2 Clinical Trials

2.3. Diabetic Neuropathy Phase 1 Clinical Trials

3. Diabetic Neuropathy Epidemiology Analysis by Countries

4. US Diabetic Neuropathy Market Insights

4.1. Marketed Drugs for Diabetic Neuropathy in US

4.2. US Diabetic Neuropathy Market Size & Forecast

4.3. US Diabetic Neuropathy Drugs Sales & Forecast

4.4. US Diabetic Neuropathy Market Share Analysis

5. Germany Diabetic Neuropathy Market Insights

5.1. Marketed Drugs for Diabetic Neuropathy in Germany

5.2. Germany Diabetic Neuropathy Market Size & Forecast

5.3. Germany Diabetic Neuropathy Drugs Sales Forecast

5.4. Germany Diabetic Neuropathy Market Share Analysis

6. France Diabetic Neuropathy Market Insights

6.1. Marketed Drugs for Diabetic Neuropathy in France

6.2. France Diabetic Neuropathy Market Size & Forecast

6.3. France Diabetic Neuropathy Product Sales Forecast

6.4. France Diabetic Neuropathy Market Share Analysis

7. Italy Diabetic Neuropathy Market Insights

7.1. Marketed Drugs for Diabetic Neuropathy in Italy

7.2. Italy Diabetic Neuropathy Market Size & Forecast

7.3. Italy Diabetic Neuropathy Product Sales Forecast

7.4. Italy Diabetic Neuropathy Market Share Analysis

8. Spain Diabetic Neuropathy Market Insights

8.1. Marketed Drugs for Diabetic Neuropathy in Spain

8.2. Spain Diabetic Neuropathy Market Size & Forecast

8.3. Spain Diabetic Neuropathy Product Sales Forecast

8.4. Spain Diabetic Neuropathy Market Share Analysis

9. UK Diabetic Neuropathy Market Insights

9.1. Marketed Drugs for Diabetic Neuropathy in UK

9.2. UK Diabetic Neuropathy Market Size & Forecast

9.3. UK Diabetic Neuropathy Product Sales Forecast

9.4. UK Diabetic Neuropathy Market Share Analysis

10. Europe Diabetic Neuropathy Market Insights

10.1. Europe Diabetic Neuropathy Market Size & Forecast

10.2. Europe Diabetic Neuropathy Product Sales Forecast

10.3. Europe Diabetic Neuropathy Market Share Analysis

11. Japan Diabetic Neuropathy Market Insights

11.1. Marketed Drugs for Diabetic Neuropathy in Japan

11.2. Japan Diabetic Neuropathy Market Size & Forecast

11.3. Japan Diabetic Neuropathy Product Sales Forecast

11.4. Japan Diabetic Neuropathy Market Share Analysis

12. Global Diabetic Neuropathy Market Insights

12.1. Global Diabetic Neuropathy Market Size & Forecast

12.2. Global Diabetic Neuropathy Product Sales Forecast

12.3. Global Diabetic Neuropathy Market Share Analysis

13. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/vu5c4h

Read this article:
2020 Insights into the Global Diabetic Neuropathy Industry - Market and Competitive Landscape - ResearchAndMarkets.com - Business Wire

Read More...

Coronavirus updates: California to release 8,000 inmates; masks ‘only way’ to prevent another shutdown, Texas Gov. says – USA TODAY

July 10th, 2020 8:45 pm

If you thought COVID-19 symptoms couldn't get worse, doctors say a new symptom has emerged. Hallucinations. USA TODAY

A spiking COVID-19 case countis straining Florida's hospital system as nearly half of its intensive care units are at least 90% full.

Mississippi has also seen a recent strain on its hospitals. Five of the largest medical centers have no ICU bed space for new patients COVID-19 or otherwise and are being forced to turn patients away.

Meanwhile, some states are scaling back reopening guidelines or adding new requirements: Some bars in Nevada will be closing again Friday and restaurants can no longer serve parties more than six people.Kentucky will join the growing list of states that require face coverings in public, too.

In New Mexico, indoor dining at restaurants and breweries will be restricted again starting Monday, and Gov. Michelle Lujan Grisham halted high school sports and said state parks will be closed to out-of-state residents.

Here are some recent developments:

Today's stats:The U.S. has surpassed 3.1 million confirmed cases of COVID-19, the disease caused by the novel coronavirus. More than133,000deaths have been confirmed, according toJohn Hopkins University data. Globally, there have been 12.3 million cases and over 556,000deaths.

What we're reading:ThreeArizona teachers shared a classroom for summer school.They thought they were being "very careful."All threecontracted COVID-19, and one died.The teachers who survived say their colleague's death is a stark reminder of the risks teachers will face if school reopens too soon.

Our live blog will be updated throughout the day. For first-in-the-morning updates,sign upfor The Daily Briefing.

R-0 may be the most important scientific term youve never heard of when it comes to stopping the coronavirus pandemic. USA TODAY

The Pac-12 will use a conference-only playing schedule for all fall sports should teams be able to compete in the face of the coronavirus pandemic, a personwith direct knowledge of the league's decision told USA TODAY Sports on Friday.

The person requested anonymity because the league had not made an announcement.

In doing so, thePac-12 joins the Big Ten in becoming the second Power Five conference to make a decisionthat could foreshadow similar changes across the entire Bowl Subdivision.

Paul Myerberg

Schools should prioritize safety and rely on local authorities inschool reopening plans, ajoint statementfrom associations of pediatricians, educators and superintendents says.

"Returning to school is important for the healthy development and well-being of children, but we must pursue re-opening in a way that is safe," says the statement from The American Academy of Pediatrics, American Federation of Teachers, the National Education AssociationandThe School Superintendents Association. "Science should drive decision-making on safely reopening schools."

The statement follows a push fromTrump to open schools across the nation andamid a nationwide debate over whether children should return to the classroom.

In an effort to prevent the spread of COVID-19 in Californiastate prisons, upto 8,000 currently incarcerated people could be released by the end of August, the state's Department of Corrections and Rehabilitation announced Friday.

"Too many people are incarcerated for too long in facilities that spread poor health. Supporting the health and safety of all Californians means releasing people unnecessarily incarcerated and transforming our justice system,"Jay Jordan, Executive Director ofCalifornians for Safety and Justice, said in a press release.

Since the start of the pandemic, the state has releasedabout 10,000 people, according to the state'sDepartment of Corrections.

Activists have repeatedly called on the governor to address the outbreak atSan Quentin prison, where more than 200 staff and more than 1,300 prisoners have active cases, and at least six inmates have died, according to local news reports.

Amid a resurgence of COVID-19 in Georgia, Gov. Brian Kemp announced Friday that the state will reactivate its makeshift coronavirus hospital at a convention center in Atlanta.

The 200-bed temporary hospital at theGeorgia World Congress Centerwas constructed in April but wound down operations at the end of May.

Nearly 3,000 people have died and more than 111,000 people have tested positive for the virus in the state.

At least 47 students at UC Berkeley tested positive for the coronavirus in just one week, and most of the new cases stem from a series of Greek life parties, university officials said.

In a message to the campus community, UniversityHealth Services Medical Director Anna Harte and Assistant Vice Chancellor Guy Nicolette said it was "becoming harder to imagine bringing our campus community back in the way we are envisioning."

"Generally, these infections are directly related to social events where students have not followed basic safety measures such as physical distancing, wearing face coverings, limiting event size, and gathering outside," the officials wrote.

Texas Gov. Greg Abbott begged Texans to mask up in a Friday interview with eastern Texas TV station CBS19, saying face coverings were "the only way"businesses could stay open.

"Its disappointing"that some local officials are refusing to enforce the states mask order, Abbott said. "If we do not all join together and unite in this one cause for a short period of time it will lead to the necessity of having to close Texas back down."

Abbott's ordereffective July 3 requires face masksin public spaces in counties with 20 or more active COVID-19 cases.The order does not apply to people eating,drinking, swimming orexercising or those under 10 years old.

Joel Shannon

West Virginia is among states with the fewest COVID-19 cases, but the state now has the highest coronavirus transmission rate in the country, the head of the state's coronavirus response said Friday.

"The virus is spreading faster person to person in West Virginia right now than in any other state in the country,"Dr. Clay Marsh.The state's "RT value" the average number of people who become infected by an infectious personis the highest in the nation, at 1.37, Marsh said. "We can see that COVID is starting in that logarithmic phase, that compounding phase."

The state has doubled its number of active cases in the last 10-14 days.

Gov. Gretchen Whitmer on Friday expanded Michigan's mask-wearing requirements, effective Monday, saying that wearing masks is the best way to reverse an increase in coronavirus cases.

The order requires the use of face coverings in crowded outdoor spaces and reiterates that individuals are required to wear a face covering whenever they are in an indoor public space. The mandate also requires any business that is open to the public to refuse entry or service to people who refuse to wear a face covering, with limited exceptions.

Paul Egan, Detroit Free Press

Shutting down states in the early days of the US COVID-19 outbreak prevented at least 250,000 deaths and as many as 750,000-840,000 hospitalizations, a new study found. Shelter-in-place orders took about two weeks to show an effect on hospitalizations and three weeks to limit the number of deaths, according to the study by researchers at the University of Iowa and National Bureau of Economic Research.

The authors, who published their results in the journal Health Affairs, also found that deaths from causes other than COVID-19 might have increased if hospitals had become overwhelmed; slowing cases saved those lives, as well, they said.

"These estimates indicate that [stay in place orders] played a key role in flattening the curves not only for cases, but also for deaths and hospitalizations, and eased pressure on hospitals from avoided COVID-19 admissions," the authors conclude.

Karen Weintraub

All 50 states had visitors from Floridathis week, according to data that 15 million U.S. mobile device users provided to the data company Cuebiq. Applying Cuebiqs sample to the whole population, approximately 1.5 million Floridians are now setting up shop in other states.

Residents have left the state in increasing numbers at a time when the crisis there got worse. In early June, just 5% of the states residents appeared in other states. That number has ticked up every week.

Cuebiqs data, which is based on cell phone locations, shows that most interstate visitors from Florida appeared in other parts of the South. About 38% of the states travelers were in Georgia at least once during the week, for example. Alabama, North Carolina, South Carolina and Tennessee also topped the list of destinations for visitors from the hard-struck state.

States outside the region saw big Florida influxes as well. New York, Texas, Pennsylvania and Ohio all had more than 50,000 visits from Florida residents in the most recent week of data, based on an extrapolation of the cell phone location data.

Matt Wynn

New data on the experimental drug remdesivir confirms it can shorten the course of COVID-19 infections and suggests it also can save lives.

Gilead Sciences, Inc., a California pharmaceutical company that makes the drug, revealed data Friday about nearly 400 patients in its late-stage clinical trial.

According to the results, 74% of patients treated with remdesivir had recovered by their 14th day of hospitalization, compared to 59% of those who did not get the drug. Nearly 8% of the patients on remdesivir had died by day 14, versus more than 12% of patients who did not receive it.

The study also found patients who took the drug hydroxychloroquine along with remdesivir fared worse than those on remdesivir alone. The company recommended against using the drugs in combination.

Remdesivir, an antiviral initially developed to treat Ebola, has not yet been approved for widespread use by the U.S. Food and Drug Administration, but it has been given emergency use authorization to treat COVID-19 patients.

Karen Weintraub

Congestion, runny nose, nausea and diarrhea are the four most recent COVID-19 symptoms that the Centers for Disease Control and Prevention added to its growing list of potential signs of the novel coronavirus.

The CDC previously said symptoms include chills, fever, muscle pain, headache, sore throat and a new loss of taste or smell. The agency now lists 11 symptoms on its website.

The additions come as health experts continue to learn more about the disease, and care for very ill COVID-19 patients is improving. Even so, the CDC states the current list doesn't include all possible symptoms for the virus.

Wyatte Grantham-Philips

Fifty-eight Major League Baseball players tested positive for the coronavirus upon reporting to their team, while an additional 13 tested positive after workouts began, according to data released by MLB on Friday.

Perhaps most disconcerting is that 10 teams reported positive test results during what MLB is calling "monitoring testing," meaning one-third of the league's teams had an infected player or staff member after workouts began last week.

Several teams have had workouts halted or curtailed while awaiting test results, and besides those testing positive, players who have come in contact with those testing positive have been temporarily sidelined, as well.

Gabe Lacques

As COVID-19 cases spikeacross, multiple states have taken measures to scale back their reopening plans. Here are some of the last moves:

Read more about states that arepause reopening or take new steps to slow the spread.

A Los Angeles Times report says that researchers are working on an upper-arm injection that would deliverantibody-rich blood plasma of COVID-19 survivors to provide potentially months of protection from the virus.

The approach is similar to one used for other diseases likehepatitis A and could be widely available across the United States, the Times reported.

However, the proposal has received push back from the federal government and pharmaceutical companies, who argue efforts in plasma-based therapy should focus on treating sick people rather than preventing infection, the Times report says.

Dr. Anthony Fauci told the newspaper that the research was promising but more work is needed to show thatcoronavirus antibodies work.

Dr. Anthony Fauci, the nation's top infectious disease expert, said Friday he has not briefed President Donald Trump in at least two months and not seen him in person at the White House since June 2, despite a coronavirus resurgence that has strained hospitals and led several states to pause reopenings.

Fauci told the Financial Times he was "sure" his messages were sent to the president even though the two have not been in close contact in the past several weeks.

The comments from the Trump administration's director of the National Institute of Allergy and Infectious Diseases came as Trump has been critical of Fauci and spoken openly about issues on which they disagree.

In a Thursday interview with Fox News' Sean Hannity, Trump said Fauci had "made a lot of mistakes" but called him a "nice man." Trump also said "most cases" of coronavirus would "automatically cure. They automatically get better."

Fauci also in the FT interview said Trump was incorrect in claiming 99% of coronavirus cases were "harmless" and may have conflated some statistics.

Nicholas Wu

COVID survivors' main symptoms can linger for weeks or even months, causing pain, trouble breathing, nightmares and even organ failure. USA TODAY

Two scientists from the World Health Organization are traveling toBeijing on Friday to lay the groundwork for an investigation into the origins of the new coronavirus.

The researchers,an animal health expert and an epidemiologist, will work with counterparts in China to "look at whether or not it jumped from species to humanand what species it jumped from," WHO spokesperson Dr. Margaret Harris said.

The team will determine the logistics, locations and participantsfor a WHO-led international mission.

The virus was first detected in the central Chinese city of Wuhan late last year. Scientists believe the novel virusoriginated in bats, transferred to another mammal then jumpedto humans.

The Trump administration this week officially began withdrawing the United Statesfrom the WHO, of which President Donald Trump and his advisers have been sharply critical.

Americans are three times as likely to know someone in their community who has been sick with the coronavirus than they did in March, according to a new survey.

More than one-third of Americans (36%) say someone they know outside of their immediate family or work has been sick with the coronavirus, according to a new survey from the Democracy Fund + UCLA Nationscape Project. That number is more than triple the number in mid-March, when it was 11%.

The survey also showed Black (11%) and Latino (11%) Americans are more likely than white Americans (7%) to have had an immediate family member get sick, according to the survey. These racial differences were not apparent in the survey from March.

Rebecca Morin

Nearly half of Florida's intensive-care units are at least 90% full, and more than 1 in 5 are completely full, according to state data.

Hospitals are increasingly strained under COVID-19, andhospitalizations across the state have jumped more than 13% just since July 1. More than 17,100 Floridians have been hospitalized for COVID-19 since the start of the pandemic.

A total of 95 hospital ICUs were at least 90% full Thursday, according to the Florida Agency for Health Care Administration. That's nearly half the 207 ICUs that the agency is tracking. At least 45 hospital ICUs were at capacity, and 46 others had only one bed available in the units.

At least 4,111 people in Florida have died from the virus, according to the state a figure that would have made it the ninth leading cause of death in Florida last year, according to Florida Department of Health statistics. Florida set a one-day record Thursday with 120 deaths. The previous high, 83, was in late April.

Frank Gluck, Fort Myers News-Press

The five largest medical centers in Mississippi have no ICU bed space for new patients coronavirus or otherwise and are being forced to turn patients away, even as COVID-19 continue to surge.

In some cases, patients are being sent to facilities out of state and as far away as New Orleans. In many hospitals, patients admitted to the ER are being forced to spend the night before they receive treatment.

"(Wednesday), five of our biggest hospitals in the state had zero ICU beds. Zero," State Health Officer Dr. Thomas Dobbs said. "Our biggest medical institutions who take care of our sickest patients have no room."

The transition from shelter-in-place to where we currently stand, with the highest number of hospitalizations since the first reported case of the coronavirus virus on March 11, has left the state "wide open," said Dr. Louann Woodward, UMMC vice chancellor for health affairs.

Justin Vicory, Mississippi Clarion Ledger

California is set to become the first state to file a lawsuit against the Trump administration over anew policy that prevents international students from staying in the U.S. if their college or university switches to online-only classes in the fall because of the coronavirus pandemic.

The announcement comes a day after some colleges and universities filed similar lawsuits or announced plans to do so.

The Trump administration revealed its new guidelines in a memo issued by Immigration and Customs Enforcement on Monday. It says that international students will have to leave the country, or face possible deportation, if their schools switch to remote learning, which many have planned to do amid the pandemic.

President Donald Trumps attack on his own health experts guidance for safely reopening schools cracked open for public display a power strugglewithin the administration that has been building for months.

Trump blasted the guidance issued by the Centers for Disease Control and Prevention on Wednesday as very tough & expensive and asking schools to do very impractical things.

But CDC Director Dr. Robert Redfield said on Thursday the guidance would stand, and his staff would provide some new documents to clarify the recommendations.

Theflare-up punctuates a conflict escalating for months, with the nations top scientists publicly sidelined in the Trump administrations initial coronavirus response. Earlier disagreements delayed the release of the reopening guidance for schools and businesses.

Public health leaders who worked at the CDC under prior presidents said they had never seen anything like this weeks open discord."It underminesleadership for everyone involved, said Dr.JeffreyKoplan, a former CDC director."It's public health malpractice to say, 'Open without worrying about anything.'"

Read more here:
Coronavirus updates: California to release 8,000 inmates; masks 'only way' to prevent another shutdown, Texas Gov. says - USA TODAY

Read More...

Tenn. Mom Accused of Fatally Shooting Daughter, 5, Then Trying to Blame Toddler Son – MSN Money

July 10th, 2020 8:45 pm

Knox County Sheriffs Office; Facebook Robin Howington and Destiny Oliver

A Tennessee woman is accused of fatally shooting her 5-year-old daughter, then trying to blame the killing on two different men and her 2-year-old son, according to multiple reports.

Robin Howington, 37, has been indicted by a grand jury. She is being held on a $500,000 bond on charges of first-degree murder, child neglect, false reporting, tampering with evidence and attempted tampering with evidence, all stemming from the Sept. 14, 2019, death of her daughter, Destiny Oliver.

The little girl was shot in the chest inside Howington's Fountain City home. She was rushed by ambulance to a nearby hospital, where she was pronounced dead shortly after arriving.

According to an indictment obtained by multiple outlets,Howington allegedly tried blaming three separate individuals for the fatal shooting.

At first, reports the Knoxville News Sentinel, which cites her indictment, Howington allegedly claimed a man she did not know found his way inside and shot Destiny once before fleeing in a black Chrysler 300.

Under questioning, Howington allegedly changed her story, claiming to police Destiny's father was the man who shot the child point blank in the chest, saying the violence unfolded soon after a heated argument between the two parents, according to the indictment.

WATE-TV reports she allegedly said that the father fled in a white Chrysler 300, the indictment states.

As police searched the surrounding area after the shooting, a gun was discovered stashed in a bush outside Howington's home.

Police allege that she told them her boyfriend who is not Destiny's father hid the gun there. However, investigators obtained video footage shot by a neighbor that allegedly shows Howington hiding the weapon, reports WVLT-TV, the indictment states.

Detectives showed the footage to Howington, who allegedly admitted stashing the gun in the bush after wiping it down, according to the indictment. She allegedly said she wanted to protect her 2-year-old son, who'd found the firearm in a closet and shot his sister.

The indictment alleges she "did unlawfully kill [Destiny Oliver] during the perpetration of aggravated child neglect."

Want to keep up with the latest crime coverage? Sign up for PEOPLE's free True Crime newsletter for breaking crime news, ongoing trial coverage and details of intriguing unsolved cases.

Howington has yet to enter pleas to the charges against her, and her attorney could not be reached for comment.

The tampering charges stem from Howington's alleged efforts to destroy her cell phone the evening of her daughter's killing.

Police allege she told them she did not want detectives finding evidence on the phone of illicit marijuana sales she had allegedly conducted, according to the indictment.

Read the rest here:
Tenn. Mom Accused of Fatally Shooting Daughter, 5, Then Trying to Blame Toddler Son - MSN Money

Read More...

Is Regeneron Pharmaceuticals Inc (REGN) a Winner in the Biotechnology Industry? – InvestorsObserver

July 10th, 2020 8:44 pm

A rating of 89 puts Regeneron Pharmaceuticals Inc (REGN) near the top of the Biotechnology industry according to InvestorsObserver. Regeneron Pharmaceuticals Inc's score of 89 means it scores higher than 89% of stocks in the industry. Regeneron Pharmaceuticals Inc also received an overall rating of 77, putting it above 77% of all stocks. Biotechnology is ranked 13 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 77 means the stock is more attractive than 77 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Regeneron Pharmaceuticals Inc (REGN) stock has fallen -3.2% while the S&P 500 has risen 0.39% as of 2:13 PM on Friday, Jul 10. REGN is down -$20.48 from the previous closing price of $640.63 on volume of 504,426 shares. Over the past year the S&P 500 is higher by 5.48% while REGN has risen 112.51%. REGN earned $19.90 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 31.1.

To screen for more stocks like REGN click here.

Read more:
Is Regeneron Pharmaceuticals Inc (REGN) a Winner in the Biotechnology Industry? - InvestorsObserver

Read More...

Boswellia Market Competitive Strategies, Growth, Recent Trends Analysis and Forecasts to 2026 | Sabinsa, Arjuna Natural, PLT Health Solutions, Alchem,…

July 10th, 2020 8:44 pm

Boswellia Market with Insights and Key Business Factors:

The latest Marketreport by a Data Bridge Market Researchwith the title[Global BoswelliaMarket Industry Trends and Forecast to 2026].In this BoswelliaMarket report, a in-depth investment analysis is offered which forecasts imminent opportunities for Boswelliamarket players and develops the strategies to grow return on investment (ROI). The Boswelliamarket report contains explicit and up-to-date information about the consumers demands, their inclinations, and their variable likings about particular product.The market studies, insights and analysis of this Boswelliamarket research report keeps marketplace clearly into the focus which aids in achieving business goal. SWOT analysis and Porters Five Forces Analysis are the two favourably used tools for structuring this market document.

Get a PDF Sample copy (including COVID-19 impact analysis and up-to 30% discount) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-Boswellia-Market

Thestudy considers the BoswelliaMarketvalue and volume generated from the sales of the following segments:Major Marketmanufacturerscovered in the BoswelliaMarketare:Sabinsa, Arjuna Natural Pvt Ltd, PLT Health Solutions, Alchem International Pvt. Ltd., Nutra Green Biotechnology Co., Ltd., Gurjar Phytochem Pvt. Ltd., S.A. Herbal Bioactives LLP, Alpspure Lifesciences Private Limited., NOW Foods, Jayshreenath Herbals, Venkatesh Naturals, Herbal Creations, Ambe Ns Agro Product Pvt Ltd, MANUS AKTTEVA, Marven Bio Chem among others.

By Type

By Source

By Application

By End Use

Based on regions, the BoswelliaMarketis classified into North America, Europe, Asia- Pacific, Middle East & Africa, and Latin AmericaMiddle East and Africa (GCC Countries and Egypt)North America (United States, Mexico, and Canada)South America(Brazil, Argentina etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Get a Sample copy (Table of Content, Charts and Figures)@https://www.databridgemarketresearch.com/toc/?dbmr=global-Boswellia-Market

Global Boswellia market is growing at a steady CAGR of 4.0% during the forecast period of 2019 to 2026 due to increasing demand of natural ingredients from geriatric population for joint health supplements.

Market Drivers:

Market Restraints:

Key Developments in the Market:

Key Benefits for BoswelliaMarket:

Click Here to avail customization of BoswelliaMarket [emailprotected]https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-Boswellia-Market

About Us:Data Bridge Marketresearch endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process Data Bridge set forth itself as an unconventional and neoteric Marketresearch and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best Marketopportunities and foster efficient information for your business to thrive in the Market.

Contact Us:Data Bridge MarketResearchUS: +1-888-387-2818UK: +44 208 089 1725Hong Kong: +852 819+2 7475Email: [emailprotected]

Read this article:
Boswellia Market Competitive Strategies, Growth, Recent Trends Analysis and Forecasts to 2026 | Sabinsa, Arjuna Natural, PLT Health Solutions, Alchem,...

Read More...

Global Liver Cirrhosis Market 2020 with (COVID-19) Impact Analysis, Sales Revenue, Development Status, Opportunity Assessment and Forecast by 2025 -…

July 10th, 2020 7:50 pm

Global Liver Cirrhosis Market 2020 by Company, Type and Application, Forecast to 2025 comprehensively provides information about the market introduction, market summary, global market revenue (revenue USD), market drivers, market restraints, market opportunities, competitive analysis, regional and country level. The report demonstrates the industry chain structure as well as macroeconomic environment analysis and development trends. The report interprets value chain structure, industrial environment along with regional analysis, application, market size, and forecast for 2020 to 2025 time-period. On the basis of intelligent analysis, the report determines investment opportunities and probable threats in the industry.

The market report is released with data tables as well as historical and forecast years represented with charts & graphs with easy to understand detailed analysis. The report covers the major details of the market, its future growth, prospects, and Industry demands analysis. The report throws light on the global Liver Cirrhosis industry sizing trend by revenue & volume, current growth factors, facts, and industry-validated market development data. The report is categorized into its respective segments by company, by country, and by application/types containing well-structured data.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/51344

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Liver Cirrhosis market.

Key Insights Enclosed in The Report:

The research study allows market professionals to stay tuned with the latest trends and segment performance. The report details growth drivers, emerging trends, market opportunities, and investment risks in various segments in the industry. Additionally, an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and the market forecast is provided. The next section is dedicated to profiling key companies in the global Liver Cirrhosis market along with the market shares they hold. Here competitors SWOT, product specifications, and peer comparison including variables such as gross margin, total revenue, segment revenue, employee size, net profit, total assets, etc are covered.

This report focuses on the global top players, covered: F Hoffman La-Roche, Gwo Xi Stem Cell Applied Technology, Johnson & Johnson, GlaxoSmithKline, Conatus Pharmaceuticals, Gilead Sciences, Intercept Pharmaceuticals, Bristol-Myers Squibb, Merck, Instituto Grifols,

In market segmentation by types, the report covers: Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis, Cardiac Cirrhosis, Cryptogenic Cirrhosis

In market segmentation by applications, the report covers the following uses: Hospitals, Specialty Clinics

The regional segmentation includes the current and forecast demand for North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa) with its further bifurcation into major countries.

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-liver-cirrhosis-market-2020-51344

Important Facts About Global Liver Cirrhosis Market Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.researchstore.biz

Link:
Global Liver Cirrhosis Market 2020 with (COVID-19) Impact Analysis, Sales Revenue, Development Status, Opportunity Assessment and Forecast by 2025 -...

Read More...

There is a strong genetic component to asthma, but it’s not the only risk factor – Insider – INSIDER

July 10th, 2020 7:48 pm

Asthma is a chronic condition that causes your airways to become inflamed leading them to swell and narrow. This makes it harder for you to breathe and can cause dangerous asthma attacks.

Asthma is often linked to other health conditions like hay fever and environmental factors including air pollution. However, research also shows that carrying certain genes can put you at greater risk of developing asthma.

Here's what you need to know about what causes asthma and how it can be passed down through families.

Scientists have identified more than one hundred specific genes that may play a role in whether or not a person develops asthma. In fact, a person with at least one biological parent with asthma is 3 to 6 times more likely to develop the condition than someone whose parents don't have asthma.

However, even if you are born with asthma-related genes, you may not develop asthma unless those genes are "turned on," likely by something in your environment. "Multiple genes may be involved and they could be triggered by a number of factors, such as viral infections," says Stanley Szefler, MD, the Director of the Pediatric Asthma Research Program at Children's Hospital Colorado.

This means that if you have asthma-related genes and suffer a bad respiratory infection as a child, this could kickstart a lifelong asthma condition. However, experts say that more research is needed to fully understand how these genes interact with the environment to cause asthma in the first place.

Doctors have identified several different types of asthma including adult-onset asthma, allergic asthma, and exercise-induced asthma. Scientists have not linked any specific genes to a particular type of asthma, Szefler says. However, there is evidence that every type of asthma has a genetic component.

In a study, published in 2008 in Twin Research and Human Genetics, researchers compared the incidence of asthma in twins to determine how strongly genes affect the likelihood of developing asthma, compared with environmental factors. The results showed that genetics plays a very large role the genes account for about 70% of your risk of developing asthma.

It's important to remember that even though genes are an important risk factor for asthma:

About half of all asthma sufferers start having symptoms as children age 5 and younger. But for people who develop asthma later in life, genes are less likely to play a role. This may be because some older people develop asthma due to lifestyle choices like smoking.

In addition to genetics, asthma may be caused by:

In many cases, experts don't know why some people develop asthma while others don't. However, there are risk factors that can increase your risk. These include:

There is no way to prevent asthma, even if you start treatment early on after your symptoms develop, says Szefler. Researchers are starting to look at whether using biologic medications containing live bacteria could work to prevent asthma, Szelfer says, "but the results are several years off."

However, even if you can't prevent asthma, there are steps you can take to prevent asthma attacks:

Asthma is an ongoing condition and you should "maintain good medical follow-up to keep the disease under control," Szefler says. You will need to make an individual treatment plan with your doctor, designed to target your symptoms and help avoid your asthma triggers.

Continued here:
There is a strong genetic component to asthma, but it's not the only risk factor - Insider - INSIDER

Read More...

Whats next for abortion legislation in the U.S.? – PBS NewsHour

July 10th, 2020 7:47 pm

The Supreme Court decision to strike down a Louisiana law on June 29 that would have restricted access to abortion in the state was broadly seen as a win for the reproductive rights movement. Some scholars and activists caution, however, that the narrow decision does not necessarily signal abortion rights will be protected by the high court in future cases.

In a surprise 5-4 decision, the conservative Chief Justice John Roberts joined liberal justices in striking down the law, which would have required abortion providers in Louisiana to have admitting privileges to a hospital within 30 miles. If upheld, the law could have shut down all but one abortion clinic in the state.

WATCH: What Supreme Court decision on Louisiana law means for U.S. abortion rights

I was sort of bracing for a defeat for the abortion providers, so in some respect, I was pleasantly surprised by Roberts joining the liberal justices in the decision, said Melissa Murray, an NYU law professor specializing in family law, constitutional law, reproductive rights and justice. But, she warned, I think its a much more muted victory than many perhaps appreciate. The chief justice is very clear that his views on abortion havent changed.

When Roberts served as an attorney in two consecutive Republican administrations those of Presidents Ronald Reagan and George H.W. Bush he helped author briefs arguing that Roe v. Wade, the landmark case that legalized abortion nationwide, was wrongly decided and should be overturned. But in his Senate confirmation hearing in 2005, he agreed that the case was settled law and said he would err toward respecting precedent.

Heres a look at the implications of the June 29 decision on June Medical Services LLC. v. Russo, and what it means for abortion rights and access in the U.S. going forward.

The Louisiana law blocked last week was the second so-called TRAP law or Targeted Regulation Against Abortion Providers to make its way to the Supreme Court within the last five years.

It was the first time an abortion case was heard since President Donald Trump filled the high courts vacancies by appointing two conservative justices, Brett Kavanaugh and Neil Gorsuch.

In reinstating the Casey standard, hes gutted Whole Womans Health. Were back to 1992.

The legal argument that TRAP laws hinge on is the idea that abortion is in some ways bad for women, according to Mary Ziegler, a law professor at Florida State University specializing in the legal history of reproduction and author of Abortion in America: A Legal History from Roe to the Present.

Ziegler said the idea behind these laws is that if abortion clinics have more stringent requirements, women will have better continuity of care. Its part of this general argument that abortion, and abortion providers, are unsafe, she said when speaking with the PBS NewsHour in February.

Kathaleen Pittman, a clinic administrator at Hope Medical Group in Louisiana and a plaintiff in the the Supreme Court case, told the NewsHour in March that the state had tried everything to decimate access to abortion care.

The situation here is already dire and this law would be the last straw for most of the remaining clinics. Were hopeful that the court will recognize how devastating this law would be for women in our state, Pittman said in March.

The Supreme Court did end up siding with the health clinic, largely because it had already ruled back in 2016 that a similar Texas rule requiring abortion providers to have hospital admitting privileges placed a substantial obstacle in the path of women seeking an abortion, constituting an undue burden on abortion access.

Citing this precedent set in the 2016 case, Whole Womans Health v. Hellerstedt, Chief Justice Roberts sided with the liberal justices in blocking the Louisiana regulation from taking effect, even though he had ruled against the Texas law while on the high court in 2016.

I joined the dissent in Whole Womans Health and continue to believe that the case was wrongly decided, Roberts wrote, citing the Texas law that was struck down in 2016. The question today however is not whether Whole Womans Health was right or wrong, but whether to adhere to it in deciding the present case.

Abortion opponents protested the Supreme Courts decision. Kristen Waggoner, the general counsel and SVP of the Alliance Defending Freedom, which signed an amicus brief in support of the Louisiana law, likened reproductive rights advocates argument that hospital admitting privileges actually endanger women to the fox guarding the hen house.

Were going to hold abortion to the same standard that we hold other doctors, Waggoner told the NewsHour. And I think the standard should be applied to protect women no matter where their feelings are on the abortion issue itself.

Louisianas Solicitor General, Elizabeth Murrill, who defended the law before the Supreme Court, also said that clinics such as the ones targeted in the June Medical Services case actually endanger womens health. Here we have a history of egregious health and safety violations by the clinics and by the doctors who work there, Murrill said in an interview with the NewsHour when the Supreme Court heard arguments for the case in March. She added that abortion providers had a vested interest in being less regulated and having less oversight.

While complications do arise from abortion in the U.S., severe consequences, such as death, are rare. A report released by the non-partisan National Academies of Sciences, Engineering and Medicine in 2018 found that abortion is largely a safe procedure. It noted, though, that TRAP laws and other regulations instituted by states such as waiting periods and pre-abortion ultrasounds can complicate and delay the procedure, making it less safe.

Even though another law targeting abortion has been struck down by the court for now, NYU Laws Murray cautioned that the narrow nature of Roberts opinion could actually galvanize anti-abortion activists to pursue more restrictive laws in the future. This is because he cited another 1992 abortion case, Casey v. Planned Parenthood, in his reasoning.

Murray noted that while the Casey decision affirmed the right to an abortion, it also lowered the standards by which courts review abortion legislation, and allowed states to put in place regulations to further the health or safety of a woman seeking an abortion, as long they do not impose an undue burden on a womans ability to obtain the procedure.

While the decision was a nominal victory for the anti-abortion side, Murray said it actually empowered states to continue restricting access to the procedure. She worries the same could happen following the June v. Russo decision.

In his opinion, Roberts wrote, the only question for a court is whether a law has the effect of placing a substantial obstacle in the path of a woman seeking an abortion of a nonviable fetus. He encouraged courts not to weigh the specific benefits against the burdens of abortion laws, as the 2016 Supreme Court decision on the Texas law did, but rather to simply decide whether the proposed legislation poses an obstacle to women who are seeking abortions.

Murray called this a more amorphous standard. In reinstating the Casey standard, hes gutted Whole Womans Health, she said. Were back to 1992. And I think what you will see is states empowered to continue restricting access, and courts no longer tethered to weighing benefits against the burdens of abortion laws like the Louisiana one, she added.

The ADFs Waggoner, though, said she saw Roberts line of decision-making as a positive step for the anti-abortion movement, as it may allow states to regulate abortion providers in a way that protects women as long as theres a reasonable relation to a legitimate state interest.

While one Louisiana abortion restriction has been settled for now, the issue is by no means going away. There are some 15 abortion cases that are just one step away from making it to the Supreme Court, according to Planned Parenthood. While some of the restrictions in question are similar to the Louisiana law, many others ban abortion at various points in pregnancy, or on the basis of disability. Others ban specific types of abortion, such as dialation and evacuation.

These laws are part of a broader strategy by the anti-abortion movement to pursue a patchwork of legislation that gradually chips away at abortion access in the hopes of eventually overturning Roe v. Wade.

As of July 1, 22 states had banned abortion between 13 and 24 weeks from a womans last menstrual period, according to the Guttmacher Institute, a research institution that advocates for abortion rights. Three states Alabama, Louisiana and Utah had attempted to ban abortion at any point in a pregnancy, but those bills were blocked by the courts.

In mid-June, Tennessee lawmakers passed a bill that would ban abortions after a fetal heartbeat is detected, as early as six weeks into a pregnancy. The Iowa legislature passed a bill that same week that would require women to wait 24 hours before receiving an abortion, and Mississippi Governor Tate Reeves signed a law banning abortion based on race, sex or genetic issues on July 1.

Some states more recently tried to limit abortions due to the COVID-19 pandemic, with Texas, for example, declaring that abortion doesnt qualify as an essential surgery. While those bans are no longer in play today they have been blocked by the courts some could return as states respond to another spike in coronavirus cases.

The Guttmacher Institutes state policy director, Elizabeth Nash, said that she would not be surprised to see states emboldened by the June Medical Services decision pursuing more restrictions similar to the Louisiana law, with the thinking that the courts will be less stringent in weighing the benefits against the burdens of such requirements.

Abortion opponents read these cases very carefully and amend their strategy based on the rulings, Nash told the PBS Newshour. It would not surprise me to see abortion restrictions next year that look to these kind of restrictions. You may see states that have, say, counseling and waiting period laws look to make them more burdensome in some way.

Laws targeting abortion providers have affected access to clinics over the past decade. Between 2011 and 2017 the number of abortion clinics in the U.S. dropped by almost 4 percent, but states in the South were more heavily impacted, with a net decline of 50 clinics 25 in Texas alone. The Midwest lost a net 33 clinics in the same time period. Both regions had the largest share of new abortion restrictions in the country.

Catherine Glenn Foster, the president & CEO of Americans United Life, argued in an interview with the Newshour last fall that disparities in access are tied to the fact that abortion is a profit-making venture: There are large parts of the country that dont have a lot of people, and those are places where there arent many abortion facilities, but thats a business decision. She said she couldnt think of anything less feminist than the sentiment that we cant have an education, career, plan for families without legalized abortion.

But reproductive rights organizations view the issue differently, and already see state-level challenges to abortion as a blow to the reproductive rights movement.

The likelihood of the Supreme Court going out of its way this year to overrule Roe vs. Wade is fairly low, but it can do the exact same thing in terms of an actual persons ability to access abortion by making it harder and harder or impossible to challenge these laws, Andrew Beck, a senior staff attorney for the Reproductive Freedom Project at American Civil Liberties Union, told the NewsHour.

Guttmachers Nash said the increasingly conservative makeup of the Supreme Court could pose a serious challenge to abortion access in the coming years.

There is a real palpable threat to abortion rights at the Supreme Court, said Nash. Its clear from Roberts opinion that he would support abortion restrictions.

Courtney Norris contributed reporting to this story.

Originally posted here:
Whats next for abortion legislation in the U.S.? - PBS NewsHour

Read More...

Global Cell Theraputics Market Value Estimated To Grow With A Healthy CAGR Rate During 2020-2025: Cell Theraputics Bristol-Myers Squibb Company…

July 10th, 2020 6:50 pm

This market research study determines the increase in changes and the aspects which are likely to have an impact on the growth of the Global Cell Theraputics Market. Increased demand for the technologies is also one of the factors, which are likely to boost the growth of the market research industry. The market research study uses several tools and techniques which are used for the determination of the growth of the Global Cell Theraputics Market.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4642747

The report is also used in the analysis of the growth rates and the threats of new entrants, which are used for the determination of the growth of the market for the estimated forecast period. Moreover, increased demand for the factors influencing the growth of the market is also one of the major aspects which is likely covered in depth in the report. One of the methods for the determination of the growth of the market is the increased use of the statistical tools, which is used for the estimation of the growth of the market for the estimated forecast period. SWOT and PESTEL analysis is one of the methods for the determination of the growth of the global Cell Theraputics market. These tools are also used for the determination of the major players for the growth of the market for the estimated forecast period.

Key vendors/manufacturers in the market:

Cell TheraputicsBristol-Myers Squibb Company (Celgene)Brainstorm Cell Therapeutics Inc.Roche (Spark Therapeutics)Bluebird BioQuanterixCrispr TherapeuticsCti BiopharmaModerna TherapeuticsPTC TherapeuticsLineage Cell TherapeuticsAtara Biotherapeutics, IncAdaptimmune

Browse the complete report @ https://www.orbisresearch.com/reports/index/global-cell-theraputics-market-2020-by-company-regions-type-and-application-forecast-to-2025

This report focuses and highlights the strategies and the trends, in which the manufacturer and the company is likely to move. The research study is also known to provide in depth analysis of the reports which is one of the key aspects for the growth of the global Cell Theraputics market. The study covers the production, sales, and revenue of various top players in the global Cell Theraputics market, therefore enabling customers to achieve thorough information of the competition and henceforth plan accordingly to challenge them head on and grasp the maximum market share. This report is filled with significant statistics and information for the consumers to attain in-depth data of the Cell Theraputics and further Cell Theraputics growth.

Global Market By Type:

Cell TheraputicsStem CellsImmunocyte

Global Market By Application:

Cell TheraputicsAllogeneic Cell TherapyAutologous Cell TherapyXenogeneic Cell Therapy

Segment type is also an important aspect of any market research study. Reports are product based, they also includes information on sales channel, distributors, traders and dealers. This helps in efficient planning and execution of supply chain management as it drastically affects the overall operations of any business. The up-to-date, complete product knowledge, end users, industry growth will drive the profitability and revenue. Cell Theraputics report studies the current state of the market to analyze the future opportunities and risks.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4642747

About Us :

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Go here to read the rest:
Global Cell Theraputics Market Value Estimated To Grow With A Healthy CAGR Rate During 2020-2025: Cell Theraputics Bristol-Myers Squibb Company...

Read More...

Global Tissue-Replacement Products Market to Witness Rapid Development During the Period 2017 2025 – Lake Shore Gazette

July 10th, 2020 6:50 pm

Tissue replacement that involves repair or replacement of structural tissues, is one of the most important application covered under tissue engineering. Structural tissues such as blood vessels, bone, cartilage, and bladder are repaired or replaced using tissue engineering that drives the demand for tissue-replacement products, thereby fueling the growth of tissue-replacement products market. In tissue engineering, living cells are utilized as engineering materials to repair the cells performing specific biochemical functions. Thus, tissue engineering on a broad level refers to the procedure of combining biologically active molecules, cells and scaffolds into functional molecules. The major goal of tissue engineering involves assembly of functional constructs to restore, maintain or regenerate damaged tissues. The most common engineered tissues used to restore damaged tissues or organs include artificial skin and cartilages approved by FDA. Regenerative medicine is also one of the broad field that is responsible for recreation of cells and rebuild tissues and whole organs. It involves tissue engineering along with incorporation of self-healing properties wherein body utilizes foreign biological material or its own system to regenerate or repair cells. These two fields tissue engineering and regenerative medicine are largely interchangeable and focus on finding cures for complex chronic disorders. Some of the most common tissue replacement products include cartilage replacement products, meniscus replacement products, tendon replacement products, suture anchors, interference screws, and laparoscopic instruments. Tissue patch/mesh is again one of the most important tissue replacement product used in tissue-replacement products market that is further categorized as biological mesh including xenografts and allografts, and synthetic mesh. However, other cellular regeneration products in the global tissue-replacement products market include chondrocyte transplant, stem cells, growth factors, gene therapy and scaffolds. Presence of extensive tissue replacement products in the medical industry coupled with their increasing demand from end user segments is anticipated to drive the growth of tissue-replacement products market. Also, some of the major end users for tissue-replacement products market include hospitals, specialized clinics, ambulatory surgical centers, research & academic institutions. Regeneration or replacement of damaged tissues is majorly done by using an existing scaffold. This technique of using scaffolds to create a new tissue is used to bioengineer lung, liver, heart and kidney tissue and proves to be a promising approach in tissue engineering.

Tissue replacement is of extreme importance as it find applications in clinically repairing or replacing the damaged or destroyed natural tissue. Tissue replacement is now-a-days extensively used in orthopedic surgery, gastrointestinal surgery and abdominal surgery. It also has wide clinical applications in craniomaxillofacial surgery, spine fusion surgery, dental implant, bone growth factor delivery and others.

To remain ahead of your competitors, request for a sample here@

https://www.persistencemarketresearch.com/samples/18802

Rising incidence of tissue injuries coupled with increasing geriatric population is anticipated to be the primary factor driving the tissue-replacement products market. Increasing obesity rate, growing disposable income along with increasing healthcare expenditure and lack of tissue substitutes to be used in surgery are some other factors fueling the growth of tissue-replacement products market.Additionally, advancements in tissue engineering coupled with increasing shift of people towards craniomaxillofacial surgery, increasing medical procedures and rising sports injuries is further anticipated to fuel the growth of tissue-replacement products market during the forecast period.However, high costs associated with tissue replacement surgery and lack of reimbursement is restraining the growth of tissue-replacement products market.

The global tissue-replacement products market is segmented on basis of product type, application type, end user and geographic region:

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/18802

On the basis of type of product, biological mesh are extensively used over conventional synthetic mesh and other tissue replacement products as biological mesh have advantages over synthetic mesh in case of contaminated wounds and offers effective results. Also, rising awareness among individuals is anticipated to propel the tissue-replacement products market over the forecast period.

Based on application, tissue-replacement products find major applications in orthopedic surgery and spinal fusion surgery on the account of rising demand for tissue-replacement products in hernia repair, skin repair, dural repair and sports injuries.

However, on the basis of geography, global tissue-replacement products market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America captured the largest shares in global tissue-replacement products market and is projected to continue same trend over the forecast period due to the growing geriatric population and rising incidence of sports injuries and increase in medical procedures. North America is followed by Europe which captures the second largest revenue shares in global tissue-replacement products market. However, Asia Pacific is expected to register a fast growth during forecast period and is anticipated to be a profitable market for new market players in global Tissue-Replacement Products market. Countries in Asia Pacific such as China and India are expected to be the fastest growing regions owing to the growing demand for tissue replacement products.

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/18802

Some of the key players present in global tissue-replacement products market are StrataGraft, Edwards Lifesciences, Medtronic PLC, Arthrex Inc., Johnson & Johnson Private Limited, C. R. Bard, Inc., Smith & Nephew, Integra LifeSciences Corporation, and others.

Visit link:
Global Tissue-Replacement Products Market to Witness Rapid Development During the Period 2017 2025 - Lake Shore Gazette

Read More...

Glasses that correct color blindness give Fargo man a bright new lease on life – INFORUM

July 10th, 2020 6:47 pm

That's the case for Fargo resident Dan Haglund, who has the most common type of red-green color blindness but special glasses are now allowing him to see the shades like everyone else, and he's excited to see more of what he's been missing his whole life.

He recently shared a video of his initial reaction to the new view on Facebook.

For roughly 8 percent of men and .5 percent of women of Northern European descent, these colors are seen in a very different way.

According to the American Academy of Ophthalmology, color blindness is the inability to see colors in a normal way, often happening when an individual can't distinguish between certain colors. In an article written for the group, author David Turbert explains how the eyes work to allow us to see.

"In the retina, there are two types of cells that detect light," he writes. "They are called rods and cones. Rods detect only light and dark and are very sensitive to low light levels. Cone cells detect color and are concentrated near the center of your vision. There are three types of cones that see color: red, green and blue. The brain uses input from these cone cells to determine our color perception."

However, when one or more of the color cone cells are absent, not working properly or show a different color than normal, the affected person perceives color in an entirely different way.

Colorblind individuals cannot see the numbers formed by the different colored dots in these images. iStock / Special to The Forum

Haglund has dealt with the most common type of color blindness scientifically known as deuteranomaly and protanomaly since birth, and has family members who are also affected.

"I know when I was in elementary school, they gave all the kids a test," he says. "And then, you know, page by page, (they asked me) 'Can you see the number in these dots?' and I could only pick out, I think there were 20 pages and I could pick out about four of the pages and the rest were just blobs."

But Haglund's perception of the world got a little brighter this week, thanks to a gift from his girlfriend.

"I wasn't anticipating (what I saw), because you wait your whole life it's like opening a present," Haglund says. "(I) waited decades to see what everyone else is seeing and then when I saw I just couldn't believe the shades. Everything's so much more vivid and brighter than I'm seeing them."

Haglund's new glasses give him the ability to see colors in a new way by enhancing the contrast between colors by filtering out light. Since his first experience with these color-enhancing glasses, Haglund says he's looking forward to experiencing a whole new side of life.

"The couple things that I came up with yesterday (that I am excited for) are sunrises and sunsets," he says. "The sky has got some amazing colors that I've never seen, and then rainbows because I think there's a color or two in the rainbow that I'm probably misidentifying. I mean, I see the colors of the rainbow, but I don't know if I'm seeing them correctly."

See the article here:
Glasses that correct color blindness give Fargo man a bright new lease on life - INFORUM

Read More...

Parasitic worms use their keen senses to wriggle through their hosts – University of Wisconsin-Madison

July 10th, 2020 6:47 pm

Parasitic filarial nematodes infect hundreds of millions of people, causing diseases such as river blindness and lymphatic filariasis, which can lead to elephantiasis, a severe swelling of the limbs.

Mosquitoes spread the parasitic worms, which engage in sophisticated migrations within their insect and mammal hosts. One worm, Brugia malayi, starts in the mosquitos gut, migrates to its flight muscles, then to its mouth. In its human host, the worm travels between the lymphatic system and the blood. Researchers have little idea how the nematodes achieve these nomadic lifestyles that are crucial for their survival.

Researchers prepare to inject an anaesthetized mosquito infected with parasitic Brugia malayi nematodes with gene-disrupting molecules to study how the nematodes rely on chemical sensation to migrate within their hosts. Courtesy of Zamanian lab

In new research, University of WisconsinMadison scientists provide the first look at the genetic underpinnings of the worms migration through their hosts. They identified two genes the nematodes use to respond to cues in their host environment. When the genes are disrupted, the worms are lost and less effective at infecting their hosts.

The genes are part of the nematodes chemosensation network, a combination of chemical-sensing proteins and nerve cells that let the parasites detect and respond to molecules in their environment. Because these responses are key for the nematodes complex life cycle, theyre a potential target for future treatments.

Were hopeful that a better understanding of how worms are transmitted between hosts and move within them may lead to new approaches for parasite treatment and control, says Mostafa Zamanian, a professor of pathobiological sciences in the UWMadison School of Veterinary Medicine and senior author of the report. The work was published in June in the journal PLOS Biology.

All animals use chemosensation. Its what allows a bee to follow the scent of a flower or a human to track down the aroma of baking cookies. The Zamanian lab figured that filarial nematodes used the same system to travel to the right part of their mosquito and human hosts at the right time by following specific chemical signatures their hosts produce.

To test this idea, the researchers mined over 40 parasite genomes to identify sensory genes in filarial parasites. Then they measured the expression of chemosensory genes throughout the parasites life cycle. They looked at chemoreceptors proteins that detect a specific signal during distinct stages of the parasites life cycles within human and mosquito hosts, when the parasites migrate to different tissues.

Mostafa Zamanian

Nicolas Wheeler

We saw chemoreceptors turned on and turned off at very specific time points, likely to help the nematodes get to the right destination at the right time, says Nicolas Wheeler, a postdoctoral researcher in the Zamanian lab and lead author of the new study.

The researchers tested whether disrupting the chemosensation network would impair the worms ability to migrate within and infect their hosts. They singled out two genes known to act as messengers for chemosensation in distantly related nematodes: OSM-9 and TAX-4.

To test OSM-9s function, they exposed the nematodes to the OSM-9-disrupting chemical nicotinamide at different stages of their life cycles. When these nicotinamide-laced worms were fed to mosquitoes, the insects ended up infected with 20 to 40 percent fewer parasites. Those nematodes that did survive in the mosquitoes were worse at migrating to the insects flight muscles compared to nematodes with normally functioning OSM-9.

The researchers also extracted larvae from mosquitoes during the stage when they can infect humans and exposed them to nicotinamide. In a petri dish experiment, the larvae became less likely to move toward chemical signals in mammalian blood. The results of the nicotinamide experiments suggested that OSM-9 is key for helping the worms navigate.

The filarial nematode Brugia malayi during the larval life stage when it can infect humans, where the parasite can cause severe swelling in the limbs known as elephantiasis. Courtesy of Zamanian lab

Using another system, the research team was able to disrupt both OSM-9 and TAX-4 while the nematodes were developing within their mosquito hosts. The researchers had to inject hundreds of mosquitoes by hand with molecules tailored to disrupt each gene finicky, time-consuming work.

Because the mosquitoes were infected with the parasites and potentially able to transmit them, the researchers had to don head-to-toe protective clothing to avoid getting bitten. Then they tested how well the nematodes could respond to chemical signatures in mammals.

The filarial nematode Brugia malayi during the lifestage when it is taken up by mosquitoes feeding on infected humans. In mosquitoes, the parasite must travel from the insects gut to its flight muscles and eventually its mouth to make it back to human hosts. Courtesy of Zamanian lab

It was worth it in the end, because we were able to show both OSM-9 and TAX-4 are involved in the infective larvas ability to crawl toward (host signals in the blood), says Wheeler. These are the first two genes to be linked to migratory behavior in these parasitic nematodes.

There are effective treatments against filarial parasites, but the complex drug regimens have potentially severe side effects, and the nematodes have developed drug resistance. There is also growing evidence that sensory systems play an important role in how parasites respond to existing antiparasitic drugs. A better understanding of how the worms detect chemical signatures and find their way within hosts could one day help researchers disrupt these critical migrations, potentially bolstering treatment.

This is a starting point, says Wheeler.

This work was funded in part by the National Institutes for Health (grants K22AI125473 and R01AI151171).

Visit link:
Parasitic worms use their keen senses to wriggle through their hosts - University of Wisconsin-Madison

Read More...

Page 443«..1020..442443444445..450460..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick